首页> 外文期刊>AJNR. American journal of neuroradiology >Two-Center Experience in the Endovascular Treatment of Intracranial Aneurysms Using the Woven EndoBridge 17 Device Including Midterm Follow-Up Results: A Retrospective Analysis
【24h】

Two-Center Experience in the Endovascular Treatment of Intracranial Aneurysms Using the Woven EndoBridge 17 Device Including Midterm Follow-Up Results: A Retrospective Analysis

机译:使用中间体后续结果的编织Endobridge 17装置的颅内动脉瘤血管内治疗两中心经验:回顾性分析

获取原文
获取原文并翻译 | 示例
           

摘要

BACKGROUND AND PURPOSE: The Woven EndoBridge device proved its effectiveness in the treatment of ruptured and unruptured intracranial aneurysms as a stand-alone device. Before 2016, Woven EndoBridge deployment required at least a 0.021-inch microcatheter. In 2016, a smaller device, the Woven EndoBridge 17 with finer size increments that used a 0.017-inch microcatheter, was introduced. We retrospectively analyzed our initial and follow-up results with the Woven EndoBridge 17 in ruptured and unruptured aneurysms. MATERIALS AND METHODS: One hundred twenty-seven intracranial aneurysms in 117 patients were scheduled for treatment with the Woven EndoBridge 17 between June 2017 and February 2019. Twenty-nine aneurysms were ruptured. RESULTS: Treatment was performed as intended in 124 of 127 cases (97.6%). Additional devices such as stents or coils were used in 12 cases (9.7%). Five thromboembolic complications and 1 hemorrhagic complication were encountered, resulting in clinical deterioration in 2 patients. The overall morbidity and mortality in the entire series have been 1.7% and 0.0% to date, respectively. The follow-up results at 3 and 12 months revealed complete occlusion in 76.1% (70/92) and 78.0% (32/41). CONCLUSIONS: The Woven EndoBridge 17 device is safe in the treatment of small broad-based aneurysms without the general need for additional devices. The low complication rate and the promising follow-up results underline the value of this technique in a growing range of endovascular treatment options for intracranial aneurysms.
机译:背景和目的:编织Endobridge器件证明了其在处理破裂和未破裂的颅内动脉瘤作为独立装置的有效性。在2016年之前,编织Endobridge部署需要至少0.021英寸的微直接管。在2016年,介绍了一种较小的装置,编织Endobridge17具有更精细的使用0.017英寸微导管的更精细的增量。我们回顾性地分析了我们的初始和后续结果,在破裂和未破裂的动脉瘤中使用编织Endobridge 17。材料和方法:117例患者中的一百二十七名颅内动脉瘤预定与编织EndoBridge 17治疗2017年6月至2019年2月。二十九个动脉瘤被破裂。结果:治疗如127例(97.6%)的124例。在12例(9.7%)中使用诸如支架或线圈等附加装置。遇到了五个血栓栓塞并发症和1个出血性并发症,导致2名患者的临床劣化。整个系列的总体发病率和死亡率分别为1.7%和0.0%至今。 3和12个月的后续结果显示76.1%(70/92)和78.0%(32/41)的完全闭塞。结论:编织Endobridge17装置在处理小型宽基动脉瘤的情况下是安全的,而没有普遍需要额外的装置。低并发症率和有希望的随访结果强调了该技术在颅内动脉瘤的血管内治疗方面的增长范围内。

著录项

  • 来源
  • 作者单位

    Klin Diagnost Radiol &

    Neuroradiol Klinikum Augsburg Augsburg Germany;

    Knappschaftskrankenhaus Bochum Langendreer Univ Klin Inst Diagnost &

    Intervent Radiol;

    Klin Diagnost Radiol &

    Neuroradiol Klinikum Augsburg Augsburg Germany;

    Knappschaftskrankenhaus Bochum Langendreer Univ Klin Inst Diagnost &

    Intervent Radiol;

    Knappschaftskrankenhaus Bochum Langendreer Univ Klin Inst Diagnost &

    Intervent Radiol;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类 放射医学;
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号